A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Tenofovir exalidex (Primary)
  • Indications Hepatitis B; Infections
  • Focus Adverse reactions
  • Sponsors ContraVir Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2017 According to a ContraVir Pharmaceuticals media release, results from this trial were presented at The International Liver Congress (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL).
    • 18 Mar 2017 Results (n=10) presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 05 Dec 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top